



# PROGRAM

## Thursday, August 28

- 8<sup>00</sup> Registration**
- 8<sup>30</sup> – 8<sup>40</sup> Welcome Address**
- 8<sup>40</sup> – 9<sup>30</sup> Francheschetti Lecture**  
*Chairman : Dr H el ene DOLLFUS (Strasbourg, France)*  
**Leber Congenital Amaurosis : from darkness to spotlight.**  
*KAPLAN J. (Paris, France).*
- 9<sup>30</sup> – 10<sup>50</sup> Symposium Innovative Therapies (Part 1)**  
*Chairman : Dr John FLANNERY (Berkeley, USA)*  
*Dr Christian HAMEL (Montpellier, France)*
- 9<sup>30</sup> – 10<sup>10</sup> Leber Congenital Amaurosis Clinical Trial.**  
*HAUSWIRTH W., CIDECIYAN A., KAUSHAL S., ALEMAN T., BYRNE B., SCHWARTZ S., BOYE S., ROMAN A., PANG J., WINDSOR E., SUMAROKA A., AGUIRRE G., FISHMAN G., HEON E., FLOTTE T., STONE E., JACOBSON S. (Philadelphia, USA).*
- 10<sup>10</sup> - 10<sup>50</sup> Gene therapy for X-linked retinoschisis.**  
*SIEVING P. (Bethesda, USA).*
- 10<sup>50</sup> – 11<sup>20</sup> Break**
- 11<sup>20</sup> – 12<sup>00</sup> Symposium Innovative Therapies (Part 2)**  
*Chairman : Dr Laurence DESJARDINS (Paris, France)*  
**Perspectives for retinoblastoma management.**  
*ABRAMSON D. (New York, USA).*
- 12<sup>00</sup> – 13<sup>15</sup> Retinoblastoma Session**  
*Chairman : Dr Theodora HADJISTILIANOU (Siena, Italy)*  
*Dr Maja BECK-POPOVIC (Lausanne, Switzerland)*
- 12<sup>00</sup> – 12<sup>15</sup> Revisiting old Drugs as Novel Agents for Retinoblastoma.**  
*ANTCZAK C., BOUNAMA A., RADU C., DJABALLAH H., ABRAMSON D. (New York, USA).*
- 12<sup>15</sup> – 12<sup>30</sup> Antiangiogenic therapy for retinoblastoma : effect of tumor burden and dose schedule in the murine LH BETATAG transgenic model.**  
*MURRAY T.G., BOUTRID H., HERNANDEZ E., SHI W., FEUER W., JOCKOVICH M.E. (Miami, USA).*
- 12<sup>30</sup> – 12<sup>45</sup> Vascular Targeting Increases Hypoxia in LHBETATAG Murine Retinoblastoma.**  
*BOUTRID H., PINA Y., CEBULLA C.M., LAMPIDIS T.J., JOCKOWICH M.E., MURRAY T.G. (Miami, USA).*
- 12<sup>45</sup> – 13<sup>00</sup> Tumor microenvironmental targeting therapy improves retinoblastoma tumor control.**  
*MURRAY T.G., BOUTRID H., PESTANA Y., SCHEFLER A. (Miami, USA).*
- 13<sup>00</sup> – 13<sup>15</sup> A French multicentric prospective study of treatment according to histopathologic features in unilateral retinoblastoma.**  
*AERTS I., SASTRE X., THEBAULT LECULEE E., BRISSE H., SAVIGNONI A., LUMBROSO-LE ROUIC L. (Paris, France).*
- 13<sup>15</sup> – 14<sup>00</sup> Lunch provided on site**
- 14<sup>00</sup> – 16<sup>00</sup> Retinoblastoma, Epidemiology, Genetics and Social Session**  
*Chairman : Dr Guillermo CHANTADA (Buenos Aires, Argentina)*  
*Dr Brenda GALLIE (Toronto, Canada)*
- 14<sup>00</sup> – 14<sup>15</sup> Retinoblastoma in developing countries. A systematic review.**  
*CANTURK S., QADDOUMI I., KHETAN V., MA Z., FURMANCHUK A. ANTONELI C., ULTAN I., SHARMA T., YENIAD B., CHANTADA G., ABRAMSON D. (New York, USA).*

- 14<sup>15</sup> – 14<sup>30</sup> **Restrictions in daily life after retinoblastoma : the view of the survivors.**  
 VAN DIJK J., OOSTROM K., OMHOF S., MOLL A., COHEN-KETTENIS P., RINGENS P., HUISMAN J.  
 (Amsterdam, The Netherlands).
- 14<sup>30</sup> – 14<sup>45</sup> **Epidemiological data of Retinoblastoma in German Children compared to other European data.**  
 DEBLING D., BLETNER M., WEBER S., JUNG I., KAATSCH P. (Mainz, Germany).
- 14<sup>45</sup> – 15<sup>00</sup> **Measuring the impact and effectiveness of a local, sustainable retinoblastoma healthcare program on survival.**  
 DIMARAS H., WHITE A., GALLIE B. (Toronto, Canada).
- 15<sup>00</sup> – 15<sup>15</sup> **Mortality among retinoblastoma patients in the Netherlands from 1862 to 2005.**  
 MOLL A.C., MAREES T., IMHOF S.M., RINGENS P.J., VAN LEEUWEN F.E. (Amsterdam, The Netherlands).
- 15<sup>15</sup> – 15<sup>30</sup> **Retinoblastoma treatment through the last 50 years: the Italian experience.**  
 HADJISTILIANOU T., DEFRANCESCO S., MOTOLESE I., BORRI M., DELUCA C., MOTOLESE E. (Siena, Italy).
- 15<sup>30</sup> – 15<sup>45</sup> **Cancer mortality among hereditary retinoblastoma survivors.**  
 MAREES T., MOLL A.C., IMHOF S.S., RINGENS P.J., VAN LEEUWEN F.E. (Amsterdam, The Netherlands).
- 15<sup>45</sup> – 16<sup>00</sup> **Survival among retinoblastoma patients treated at Kenyatta National Hospital, Kenya – A retrospective audit.**  
 KIMANI K., GICHIGO N., KARIUKI M.M. (Nairobi, Kenya).
- 16<sup>00</sup> – 16<sup>30</sup> Break**
- 16<sup>30</sup> – 18<sup>45</sup> Ophthalmic Genetics Session**  
 Chairman : Dr Francis MUNIER (Lausanne, Switzerland)  
 Dr Elise HEON (Toronto, Canada)
- 16<sup>30</sup> – 16<sup>45</sup> **New international classification of corneal dystrophies (CD).**  
 LISCH W. (Hanau, Germany).
- 16<sup>45</sup> – 17<sup>00</sup> **Dissecting the genetics of glaucoma.**  
 RUDDLE J.B., MACKEY D.A. (East Melbourne, Australia).
- 17<sup>00</sup> – 17<sup>15</sup> **Molecular analysis of italian patients affected by congenital glaucoma.**  
 GIUFFRE I., MAGLI A., MASELLI E., VADALA P., PIOZZI E., MAROCCHI A., PATROSSO M., CAPOZZI P., PENCO S. (Roma, Italy).
- 17<sup>15</sup> – 17<sup>30</sup> **Genetic basis of non syndromic micro-anophthalmia.**  
 CHASSAING N., VIGNOUROUX A., LEQUEUX L., MARTIN D., RIO M., KAPLAN J., LACOMBE D., HETCHEVERS H., CALVAS P. (Lille, France).
- 17<sup>30</sup> – 17<sup>45</sup> **Mutation in the human homeobox gene NKX5-3 causes a novel oculo-auricular syndrome.**  
 MUNIER F.L., SCHORDERET D.F. (Lausanne & Sion, Switzerland).
- 17<sup>45</sup> – 18<sup>00</sup> **Nance-Horan syndrome : Clinico-Molecular analysis in 25 Families.**  
 TOUTAIN A., MERCIER S., DESSAY B., RONCE N., DE RAVEL T., KAPLAN J., HERON D., NEMETH A., HOLFORST-HOSTEE Y., BURN J., GOODSHIP J, HENNEKAM R., PLOMP A., ROSSI A., WALGREN PETERSSON C., NEWBURY-ECOB R., OYEN N., BITOUN P., HARTSFIELD J. (Tours, France).
- 18<sup>00</sup> – 18<sup>15</sup> **Phenotypic spectrum of STRA6 mutations : from Matthew-Wood syndrome to non-lethal syndromic microphthalmia.**  
 CHASSAING N., GOLZIO C., ODENT S., LEQUEUX L., VIGNOUROUX A., MARTINOVIC-BOURIEL J., DELEZOIDE A.L., ATTIE-BITACH T., MANOUVRIER-HANU S., ETCHEVERS H.C., CALVAS P. (Toulouse, France).
- 18<sup>15</sup> – 18<sup>30</sup> **Outcome of removal of a dislocated lens and suturing of a posterior chamber lens implant in 130 eyes of 75 patients with the Marfan syndrome.**  
 HATEF E., JASTRI S., GEHLBACH P., MAUMENEE I.H. (Baltimore, USA).
- 18<sup>30</sup> – 18<sup>45</sup> **Ten years of malformations of eye in Alsace : epidemiologic and clinical study and evaluation of prenatal diagnosis.**  
 DORAY B., DOTT B., CORDIER C., DOLK H., DOLLFUS H. (Strasbourg, France).
- 18<sup>45</sup> – 20<sup>30</sup> Cocktail – Wine tasting**  
 Cave des Hospices Civils

# Friday, August 29

- 8<sup>30</sup> – 12<sup>20</sup> Symposium Innovatives Therapy (Part 3)**  
*Chairman : Dr Alan BIRD (London, UK)*  
*Dr Jean-Louis MANDEL (Strasbourg, France)*
- 8<sup>30</sup> – 9<sup>10</sup> Neuroprotection Of Cone Photoreceptor Cells : From Cell Therapy To Protein Therapy**  
*SAHEL J.A. (Paris, France).*
- 9<sup>10</sup> – 9<sup>50</sup> Gene transfer and expression of “photoswitches” confers light sensivity to retinal ganglion cells.**  
*FLANNERY J. (Berkeley, USA).*
- 9<sup>50</sup> - 10<sup>30</sup> Development of cell transplantation strategies for the treatment of retinal degeneration.**  
*ALI R. (London, UK).*
- 10<sup>30</sup> – 11<sup>00</sup> Break**
- 11<sup>00</sup> – 11<sup>40</sup> Nanoparticles for a cure of inherited eye disorders.**  
*NAASH M. (Oklahoma City, USA).*
- 11<sup>40</sup> - 12<sup>20</sup> Retinal implants – A perspectives.**  
*ZRENNER E. (Tuebingen, Germany).*
- 12<sup>20</sup> – 12<sup>40</sup> General Symposium Panel Discussion**
- 12<sup>40</sup> – 13<sup>00</sup> Business Meeting ISGEDR**
- 13<sup>00</sup> – 14<sup>00</sup> Lunch provided on site**
- 14<sup>00</sup> – 16<sup>30</sup> Retinoblastoma Session**  
*Chairman : Dr Laurence DESJARDINS (Paris, France)*  
*Dr Helen CHAN (Toronto, Canada)*
- 14<sup>00</sup> – 14<sup>15</sup> Criteria defining the duration of chemoreduction in retinoblastoma - a retrospective analysis.**  
*BECK POPOVIC M., ABOUZEID H., FAOUZI M., PICA A., BALMER A., MUNIER F. (Lausanne, Switzerland).*
- 14<sup>15</sup> – 14<sup>30</sup> Treatment results in patients with retinoblastoma and invasion to the resection margin of the optic nerve.**  
*CHANTADA G.L., FANDINO A., GUITTER M., RASLAWSKI E., VAIANI E., DE DAVILA M. (Buenos Aires, Argentina).*
- 14<sup>30</sup> – 14<sup>45</sup> Multiple relapsed intraocular retinoblastoma cured by multidrug resistance-reversal chemotherapy with focal therapy.**  
*CHAN H.S.L., HEON E., BUDNIG A., DIMARAS H., GALLIE B.L. (Toronto, Canada).*
- 14<sup>45</sup> – 15<sup>00</sup> Retinoblastoma : risk factors for recurrences after conservative treatment.**  
*IMHOF S.M., MOLL A., SNELLEN E. (Amsterdam, The Netherlands).*
- 15<sup>00</sup> – 15<sup>15</sup> The presence of ganglioside GD2 in the aqueous of children with retinoblastoma.**  
*CHANTADA G.L., MONTERO CARCABOSO A., FANDINO A., GUITTER M., BRAMUGLIA G., ABRAMSON D. (New York, USA).*
- 15<sup>15</sup> – 15<sup>30</sup> A phase I study of periocular topotecan in children with intraocular retinoblastoma.**  
*CHANTADA G.L., MONTERO CARCABOSO A., FANDINO A., GUITTER M., BRAMUGLIA G., ABRAMSON D. (New York, USA).*
- 15<sup>30</sup> – 15<sup>45</sup> Clinicopathologic and imaging correlation after "Rescue" therapy of advanced recurrent resistant RB using intraarterial melphalan. Caution : eye loss from side effects rather than active disease.**  
*PATON K., STRAHLENDORF C., WHITE V., HERAN R., GALLIE B., ABRAMSON D., GOBIN P. (Vancouver, Canada).*
- 15<sup>45</sup> – 16<sup>00</sup> Risk factors influencing unsatisfactory outcomes in treatment of retinoblastoma.**  
*KRSTIC V., OBUCINA D., KOSANOVIC-JAKOVIC N., LATKOVIC Z., DJUROVIC J., MARKOVIC V. (Belgrade, Serbia).*

- 16<sup>00</sup> – 16<sup>15</sup> **Orbital retinoblastoma: clinical patterns and treatment.**  
*HADJISTILIANOU T., GALLUZZI P., MENICACCI F., ACQUAVIVA A., DELUCA C., BORRI M.,  
DEFRANCESCO S., MOTOLESE P. (Siena , Italy).*
- 16<sup>15</sup> – 16<sup>30</sup> **Conservative treatment for retinoblastoma with reduced cycles of chemoreduction and  
intensive local chemotherapies.**  
*YANAGISAWA T., SUZUKI S., KANEBO A. (Hidaka, Japan).*
- 16<sup>30</sup> – 19<sup>00</sup> **Poster Session**  
*Salle des Fêtes, Hôpital Civil*
- 19<sup>00</sup> – 20<sup>30</sup> **Wine & Cheese party and Jazz – Salsa concert**  
*Salle des Fêtes, Hôpital Civil*

## Saturday, August 30

- 8<sup>15</sup> – 9<sup>30</sup>** **Retinoblastoma Session**  
*Chairman :* *Dr François DOZ (Paris, France)*  
*Dr Annette MOLL (Amsterdam, The Netherlands)*
- 8<sup>15</sup> – 8<sup>30</sup>** **Treatment of unilateral retinoblastoma (RB) with buphthalmia or radiological optic nerve invasion (RONI) at diagnosis.**  
*AERTS I., VINTI L., LUMBROSO LE ROUIC L., SAVIGNONI H., BRISSE H., DOZ F., DESJARDINS L. (Paris, France).*
- 8<sup>30</sup> – 8<sup>45</sup>** **Critical therapeutic decision making in metastatic retinoblastoma based on mutation analysis of minimal residual disease.**  
*CHAN H.S.L., RUSHLOW D., HEON E., DIMARAS H., DOYLE J., GALLIE B.L. (Toronto, Canada).*
- 8<sup>45</sup> – 9<sup>00</sup>** **Stage 4 & trilateral retinoblastoma : update New York date support the cog aret 0321 strategy.**  
*DUNKEL I.J., ABRAMSON D.H. (New York, USA).*
- 9<sup>00</sup> – 9<sup>15</sup>** **Cyclosporin-modulated chemotherapy & autologous stem cell transplant for extraocular metastatic retinoblastoma (RB).**  
*CHAN H.S.L., HEON E., DOYLE J., DIMARAS H., BABYN P., GALLIE B.L. (Toronto, Canada).*
- 9<sup>15</sup> – 9<sup>30</sup>** **Is it possible to achieve tumor control in adult-onset retinoblastoma (RB) ?**  
*KHETAN V., LINGAM G., SHARMA T., NAGPALA. (Chennai, India).*
- 9<sup>30</sup> – 10<sup>30</sup>** **Ellsworth Lecture**  
*Chairman :* *Dr Elias TRABOULSI (Cleveland, USA)*  
**The impact of new knowledge on retinoblastoma families.**  
*GALLIE B. (Toronto, Canada)*
- 10<sup>30</sup> – 11<sup>00</sup>** **Break**
- 11<sup>00</sup> – 13<sup>00</sup>** **Retinoblastoma Session**  
*Chairman :* *Dr Timothy MURRAY (Miami, USA)*  
*Dr Ashwin REDDY (London, UK)*
- 11<sup>00</sup> – 11<sup>15</sup>** **Retinoblastoma and microdeletion syndrome : identification of PCDH8 as a candidate for developmental delay.**  
*DEHAINAULT C., MICHAUX D., CASTERA L., AERTS I., DESJARDINS L., STOPPA-LYONNET D., GAUTHIER-VILLARS M., HOUDAYER C. (Paris, France).*
- 11<sup>15</sup> – 11<sup>30</sup>** **Heterogenous interstitial 13q deletions in patients with retinoblastoma.**  
*MITTER D., ULLMANN R., MURADYAN A., LOHMANN D. (Essen, Germany).*
- 11<sup>30</sup> – 11<sup>45</sup>** **Patients with initial diagnosis of sporadic unilateral retinoblastoma : who develops a tumor in the other eye ?**  
*LOHMANN D.R., BORNFELD N., JURKLIES C., LEHNERT T., BOES T., WEBER S. (Essen, Germany).*
- 11<sup>45</sup> – 12<sup>00</sup>** **Detection of mosaic RB1 mutations in families with retinoblastoma.**  
*GALLIE B.L., RUSHLOW D., PIOVESAN B., ZHANG K., PRIGODA-LEE N.L., MARCHONG M.N., CLARK R.D. (Toronto, Canada).*
- 12<sup>00</sup> – 12<sup>15</sup>** **Unilateral genetic analysis when no tumor DNA is available : cost-benefit analysis.**  
*VANDEZANDE K.E., ISUFLARI H., MCKAY J., PIOVESAN B., PRIGODA-LEE N., RUSHLOW D., ZHANG K.E., GALLIE B.L. (Toronto, Canada).*
- 12<sup>15</sup> – 12<sup>30</sup>** **Role of intensive screening in the prognosis of familial retinoblastoma.**  
*DESJARDINS L., LUMBROSO-LEROUIC L., LEVY-GABRIEL C., DE ROTSHILD P., DENDALE R., SASTRE X., ESTEVE M., DOZ F., BOURS D., SAVIGNONI A., AERTS I. (Paris, France).*
- 12<sup>30</sup> – 12<sup>45</sup>** **Reproductive decision-making : a qualitative study among couples at increased risk of having a child with retinoblastoma.**  
*DOMMERING C.J., VAN DEN HEUVEL M.R., IMHOF S.M., MOLL A.C., MEIJERS-HEIJBOER H., HENNEMAN L. (Amsterdam, The Netherlands).*
- 12<sup>45</sup> – 13<sup>00</sup>** **The effect of educational posters of the red reflex on referrals to a paediatric ophthalmology clinic.**  
*REDDY M.A., SULLIVAN A., HINDOCHA M. (London, UK).*
- 13<sup>00</sup> – 14<sup>00</sup>** **Lunch provided on site**

- 14<sup>00</sup> – 16<sup>00</sup> Ophthalmic Genetics Session**  
*Chairman : Dr Jean-Michel ROZET (Paris, France)*  
*Dr Giuliana SILVESTRI (Belfast, Ireland)*
- 14<sup>00</sup> – 14<sup>15</sup> **Clinical and molecular investigations in patients with macular autofluorescent deposits.**  
 MEUNIER I.A., ARNDT C., SENECHAL A., MAZOIR E., LOPEZ S., DHAENENS C.M., ALLORGE D., BOCQUET B., HAMEL C. (Montpellier, France).
- 14<sup>15</sup> – 14<sup>30</sup> **Morphological analysis of retinal dystrophies with drusenoid deposits.**  
 GERTH C., ZAWADZKI R.J., WERNER J.S., HEON E. (Toronto, Canada).
- 14<sup>30</sup> – 14<sup>45</sup> **Intravitreal injection of ranibizumab for choroidal neovascularisation associated with hereditary macular dystrophies.**  
 ZERBIB J., QUERQUES G., ANGULO BOCCO M.C., COSCAS G., SOUBRANE G., SOUIED E.H. (Créteil, France).
- 14<sup>45</sup> – 15<sup>00</sup> **Cohort of patients with retinal dystrophies and optic neuropathies : results of clinical diagnosis and mutation research.**  
 BOCQUET B., HUMBERT G., SURGET M.O., SENECHAL A., ALLORGE D., MATI-BONNEAU P., DHAENENS C.M., KAPLAN J., ROUX A.F., BLANCHET C., MEUNIER I., HAMEL C. (Montpellier, France).
- 15<sup>00</sup> – 15<sup>15</sup> **Molecular etiology of Stargardt disease in Newfoundland and Labrador.**  
 GREEN J., WILKINS L., HATCH K., WHELAN J., BAUTISTA D., MOORE S., YOUNG T.L. (Newfoundland, Canada).
- 15<sup>15</sup> – 15<sup>30</sup> **RPGR genotype and phenotypes in an Australian clinic population.**  
 RUDDLE J.B., EBENEZER N., KEARNS L., MULHALL L., HARDCASTLE A., MACKAY D.A. (East Melbourne, Australia).
- 15<sup>30</sup> – 15<sup>45</sup> **Generation of a genotyping micro-array containing known and novel CSNB mutations.**  
 ZEITZ C., LABS S., FORSTER U., KROES H.Y., DE BAERE E., LEROY B.P., CREMERS FPM, WITTMER M., VAN DENDEREN M.M., SAHEL J.A., AUDO I., POLOSCHKE C.M., MOHAND-SAÏD S., FLEISCHHAUER J., HÜFFMEIER U., MOSKOVA-DOUMANOVA V., LEVIN A., HAMEL C., LEIFERT D., MUNIER F., SCHORDERET F., ZRENNER E., PREISING M., LORENZ B., WISSINGER B., KOHL S., BERGER W. (Zurich, Switzerland).
- 15<sup>45</sup> – 16<sup>00</sup> **A common NYX mutation in Flemish patients with X-linked CSNB.**  
 LEROY B.P., BUDDÉ B.S., WITTMER M., DE BAERE E., BERGER W., ZEITZ C. (Ghent, Belgium).
- 16<sup>00</sup> – 16<sup>30</sup> Break**
- 16<sup>30</sup> – 17<sup>30</sup> Ophthalmic Genetics Session**  
*Chairman : Dr Irène MAUMENEE (Baltimore, USA)*  
*Dr Josseline KAPLAN (Paris, France)*
- 16<sup>30</sup> – 16<sup>45</sup> **Pheno- and Genotype in X-linked Idiopathic Nystagmus Caused by Mutations in FRMD7.**  
 GOTTLÖB I.V., THOMAS S., PROUDLOCK F., RAYMOND L., TREMBATH R., TARPEY P. (Leicester, UK).
- 16<sup>45</sup> – 17<sup>00</sup> **Assessment of the role of the RdCVF gene, TXNL6, as a potential modifier of the severity of retinal degeneration in BBS patients.**  
 HEON E., SHEKHAR T. (Toronto, Canada).
- 17<sup>00</sup> – 17<sup>15</sup> **Ocular findings of primary oxalosis in three children.**  
 DELBEKE P., LEROY B.P., RAES A. (Ghent, Belgium).
- 17<sup>15</sup> – 17<sup>30</sup> **Cobalamin C disease is a metabolic disorder with retinal degeneration.**  
 ALCORN D.M. (Stanford, USA).
- 17<sup>30</sup> – 18<sup>30</sup> Case presentation**  
*Chairman : Dr Bart LEROY (Ghent, Belgium )*  
*Dr Elias TRABOULSI (Cleveland, USA)*

**The association of an epibulbar dermoid and Duane syndrome in a patient with a SALL1 mutation (Townes-Brocks Syndrome).**

REDDY M.A., BARRY J.S. (London, UK).

**A splice site mutation in CYP27A1 causes Cerebro Tendinous Xanthomatosis (CTX) in association with pulverulent cataracts in a family with pseudodominant developmental delay.**

PATEL H.I., CHAN M., JOYCE S., MEYER E., IBRAHIM K., MAHER E.R., REDDY M.A. (London, UK).

**A New Variant of Pierson Syndrome Resulting in Bilateral Retinal Detachment and Nephrotic Syndrome.**

*MOHNEY B.J., PULIDO J.S., LINDOR N.M., CONSUGAR M.B., PETERS J., HOGAN M.C., ELDAHDAH L., HARRIS P.C. (Rochester, USA).*

**A puzzling maculopathy with inner retinal dysfunction.**

*AUDO I., MOHAND-SAID S., SAHEL J.A. (Paris, France).*

**Bilateral congenital epiretinal membranes identify a severe phenotype of neurofibromatosis type 2.**

*SISK R.A., BERROCAL A.M., SCHEFLER A.C., OUBOVY S.R. (Miami, USA).*

**Identification of a RPGR mutation in a male sporadic patient presumed to be affected with Stargardt disease.**

*ROZET J.M., DELPHIN N., GHAZI I., DUFIER J.L., ROCHE O., KAPLAN J. (Paris, France).*

**A rare association of trigonocephaly, unilateral microphthalmia and contralateral iris coloboma.**

*BENNOUNA-GREENE V., GIRARD-LEMAIRE F., CARELLE N., FLORI E., DOLLFUS H. (Strasbourg, France).*

**Harboyan syndrome due to novel mutations in the borate transporter gene SLC4A11.**

*DE ZAEYTIJD J., VITHANA E.N., MEIRE F., RAEMDONCK T., CLAERHOUT I., DE BAERE E., KESTELYN P., LEROY B.P. (Ghent, Belgium).*

**20<sup>00</sup>**

**Gala Dinner**  
*Kammerzell House*